SYS 6005
Alternative Names: RB-164; SYS-6005Latest Information Update: 15 Apr 2025
At a glance
- Originator CSPC Pharmaceutical Group
- Developer CSPC Pharmaceutical Group; Radiance Biopharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours